A bug in Limit Break's Payment Processor, used by Magic Eden's former Ethereum marketplace, has allowed attackers to drain NFTs and Wrapped Ether (WETH) from users' wallets since September 24, 2026. Over 530 WETH and thousands of NFTs have been stolen across multiple networks including Ethereum and ApeChain. Users must revoke approvals for two specific contracts on Ethereum, ApeChain, Polygon, and Base to stop further losses, as cancelling listings or using hardware wallets does not protect against this exploit. The incident highlights risks of unlimited token approvals and the need for regular approval management even after marketplaces shut down.
The Magic Eden and Limit Break exploit involving WETH and NFTs provides context for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 25, 2026 19:31 WIB: out of 50 major cryptocurrencies, 44 rose and 5 fell today. Kusama (KSM) led with an 8.57% gain at Rp84.762 and a typical hold time of 79 days, contrasting with Synthetix (SNX) which also rose 8.18% to Rp4.613 but saw 93% sell order activity. EOS.IO (EOS) increased 8.13% to Rp12.649 with a typical hold time of 87 days.
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
Bank of America downgraded Nike to Underperform and cut its price target to $30, citing a delayed sales recovery now expected a full fiscal year later. The bank highlighted risks including slowing North America wholesale, weak demand in China, produc...
